PCRXPacira BioSciences, Inc.
Is it safe?
Nothing alarming, nothing pristine: comfortable debt (A) and big price swings.
Investment-grade balance sheet. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -86% · now at/near its 52-week high.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can PCRX take a bad year?
Pacira BioSciences, Inc. carries $112M of net debt at 1.47× EBITDA: a load its earnings can carry.
Net debt · as at Q2 2026 · under two and a half years of EBITDA, comfortable
- Net debt / EBITDA
- 1.47×
Net debt / EBITDA
- Interest cover
- 1.28×
Interest cover · operating profit barely covers the interest bill
- Annualised volatility
- 51%
Annualised volatility · roughly twice as jumpy as the market
Details›
- Total debtQ2 2026
- $363M
- Cash and short-term investments
- $251M
- Net debt
- $112M
- EBITDA, trailing twelve months
- $76M
- Operating profit, trailing twelve months
- $20M
- Debt / equity
- 0.54×
- Total debt / EBITDA
- 4.75×
- Annualised volatilitytwo years of daily moves
- 51%
- Worst drawdown on file
- −86%
- Below its 52-week high
- 0.00%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Drug Manufacturers, Specialty & Generic
Ranks #19 of 41 by RyuScore